COMP <GO>
AKTS vs RIGL // ALTMAN Z-SCORE & DEBT/EQUITY
Aktis Oncology Inc. (NASDAQ) VS. Rigel Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AKTS 0
— RIGL 2
■ METRIC PARITY
LAST: $15.93 (-5.46%) • MKT CAP: $937.2M
balance-sheet
—
LAST: $51.31 (-0.27%) • MKT CAP: $961.1M
balance-sheet
3.64
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKTS VS. RIGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKTS | RIGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 93.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 28.20% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 7.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 7.87% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 42.60% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 64.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | 3.64 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 64.9 | -20.60 | RIGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $937.2M | $961.1M | -$23.9M | RIGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKTS REV | RIGL REV | AKTS GROSS % | RIGL GROSS % | AKTS FCF | RIGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $294.3M | — | 93.3% | — | $75.7M |
| FY 2024 | — | $179.3M | — | 89.6% | — | $31.5M |
| FY 2023 | — | $116.9M | — | — | — | -$5.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKTS // BETA —
RIGL // BETA —